Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.22 USD
-0.05 (-2.20%)
Updated May 6, 2024 04:00 PM ET
After-Market: $2.22 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.22 USD
-0.05 (-2.20%)
Updated May 6, 2024 04:00 PM ET
After-Market: $2.22 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Zacks News
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Jun 7, 2021
by Zacks Equity Research
Companies in the news are: REGN, CHRS, SENS, CGEM
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
by Anirudha Bhagat
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
by Tirthankar Chakraborty
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.